Yousif Capital Management LLC Reduces Holdings in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Yousif Capital Management LLC lowered its holdings in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 6.0% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 16,668 shares of the company’s stock after selling 1,060 shares during the quarter. Yousif Capital Management LLC’s holdings in Amphastar Pharmaceuticals were worth $1,031,000 as of its most recent SEC filing.

Several other large investors have also modified their holdings of AMPH. Shaker Investments LLC OH increased its position in shares of Amphastar Pharmaceuticals by 136.0% during the 4th quarter. Shaker Investments LLC OH now owns 49,078 shares of the company’s stock worth $3,035,000 after purchasing an additional 28,283 shares during the last quarter. Jacobs Levy Equity Management Inc. increased its position in shares of Amphastar Pharmaceuticals by 44.8% during the third quarter. Jacobs Levy Equity Management Inc. now owns 554,850 shares of the company’s stock valued at $25,518,000 after acquiring an additional 171,642 shares during the last quarter. Walleye Capital LLC purchased a new stake in shares of Amphastar Pharmaceuticals in the 3rd quarter valued at approximately $1,833,000. Charles Schwab Investment Management Inc. lifted its holdings in shares of Amphastar Pharmaceuticals by 7.3% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 352,378 shares of the company’s stock worth $16,206,000 after acquiring an additional 24,116 shares during the last quarter. Finally, Rafferty Asset Management LLC acquired a new position in shares of Amphastar Pharmaceuticals in the 3rd quarter worth approximately $205,000. Institutional investors and hedge funds own 65.09% of the company’s stock.

Amphastar Pharmaceuticals Stock Down 0.5 %

Shares of NASDAQ AMPH opened at $42.46 on Friday. The stock has a market cap of $2.04 billion, a P/E ratio of 16.46, a PEG ratio of 1.02 and a beta of 0.85. The business’s fifty day simple moving average is $43.48 and its 200-day simple moving average is $50.75. Amphastar Pharmaceuticals, Inc. has a 12-month low of $35.93 and a 12-month high of $67.66. The company has a current ratio of 2.17, a quick ratio of 1.70 and a debt-to-equity ratio of 0.92.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last issued its quarterly earnings results on Wednesday, February 28th. The company reported $0.81 earnings per share for the quarter, missing the consensus estimate of $0.84 by ($0.03). The company had revenue of $178.11 million for the quarter, compared to analysts’ expectations of $174.90 million. Amphastar Pharmaceuticals had a return on equity of 26.95% and a net margin of 21.34%. As a group, equities analysts predict that Amphastar Pharmaceuticals, Inc. will post 3.41 EPS for the current fiscal year.

Insider Buying and Selling

In other news, Director Michael A. Zasloff sold 12,500 shares of the firm’s stock in a transaction on Tuesday, March 5th. The shares were sold at an average price of $47.18, for a total value of $589,750.00. Following the sale, the director now directly owns 21,326 shares in the company, valued at approximately $1,006,160.68. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Over the last ninety days, insiders have sold 14,000 shares of company stock worth $655,145. Company insiders own 27.10% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have commented on the company. JPMorgan Chase & Co. initiated coverage on Amphastar Pharmaceuticals in a research note on Tuesday, March 5th. They set an “overweight” rating and a $60.00 price target on the stock. Needham & Company LLC reissued a “hold” rating on shares of Amphastar Pharmaceuticals in a research note on Wednesday, April 10th. Finally, StockNews.com lowered shares of Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, February 29th. Three research analysts have rated the stock with a hold rating and two have given a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $66.00.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.